Core Viewpoint - The establishment of the Life Omics Professional Committee aims to enhance the development and application of multi-omics analysis technologies, promoting collaboration among academia, industry, and healthcare to support innovation in life and health sciences [2][15]. Group 1: Establishment of the Committee - The Life Omics Professional Committee was officially established during the 21st Beijing Conference on Instrumental Analysis (BCEIA 2025) held from September 10-12, 2025 [3][7]. - The committee's formation was approved by the Chinese Society for Analytical Testing, emphasizing the need for interdisciplinary collaboration in omics research [7][11]. - The first election of committee members resulted in 133 elected members, with notable appointments including Professor Cai Zongwei as the Chair and several Vice Chairs from prestigious institutions [11][15]. Group 2: Forum Discussions and Innovations - The Life Omics Forum focused on five key areas: omics in biological and medical analysis, environmental analysis, imaging analysis, instrument technology, and big data analysis [11][17]. - Experts presented advancements in mass spectrometry, highlighting its evolution towards high precision and throughput, including applications in chiral molecule analysis and spatial metabolomics [17][18]. - Innovative methods combining secondary electrospray ionization and atmospheric pressure photoionization significantly improved the visualization of metabolites in complex tissues, showcasing the potential of multi-omics integration in drug development and precision medicine [18][20]. Group 3: Applications and Future Directions - The forum illustrated the broad applications of mass spectrometry in life sciences, drug development, and environmental monitoring, indicating a trend towards deeper integration of analytical technology with clinical and practical applications [20]. - Research on environmental health revealed the accumulation of carcinogens and persistent pollutants, underscoring the critical role of mass spectrometry in public health risk assessment [20]. - The discussions emphasized the acceleration of China's life omics research in methodological innovation and technology integration, aligning with international advancements [20].

特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 雪迪龙 8月4日晚间发布公告称 ， 北京雪迪龙科技股份有限公司拟与北京怀柔硬科技创新服务有限公司共同出资设立 控股子公司怀众质谱 （ 北京 ） 技术有限公司 。 控股子公司将聚焦质谱技术领域 ， 组织开展质谱共性技术 、 关 键核心部件的研发 ， 组织开展质谱新技术验证 、 评价及应用推广 ， 促进质谱行业交流合作 ， 推动行业发展 。 2024年1至12月份 ， 雪迪龙的营业收入构成为 ： 仪器仪表占比93.16% ， 其他占比6.84% 。 | 转 载 ： 须 本 号 授 权 ， 请 联 系 主 编 | 来 源 ： 雪 球 | 责 编 ： 安 安 | 视 觉 ： 长 艳 柱 子 发 文不易 ， 请 帮 小 编 点 下 "❤️" | 版 权 ： 本 文 部 分 素 材 源 自 网 络 ， 版 权 归 原 作 者 所 有 ， 观 点 代 表 作 者 本 人 ， 不 代 表 本 号立 场 ...

雪迪龙（SZ 002658，收盘价：8.01元）8月4日晚间发布公告称，北京雪迪龙科技股份有限公司拟与北 京怀柔硬科技创新服务有限公司共同出资设立控股子公司怀众质谱（北京）技术有限公司。控股子公司 将聚焦质谱技术领域，组织开展质谱共性技术、关键核心部件的研发，组织开展质谱新技术验证、评价 及应用推广，促进质谱行业交流合作，推动行业发展。 2024年1至12月份，雪迪龙的营业收入构成为：仪器仪表占比93.16%，其他占比6.84%。 （文章来源：每日经济新闻） ...

Core Viewpoint - The article emphasizes the growing importance of mass spectrometry technology in clinical diagnostics, driven by the need for earlier detection, more precise diagnosis, and comprehensive evaluation in the context of precision medicine and individualized treatment [1]. Group 1: Industry Trends - The trend in clinical diagnostics is moving towards "earlier detection, more precise diagnosis, and comprehensive evaluation," which aligns with the advancements in precision medicine [1]. - Mass spectrometry is recognized for its high sensitivity, specificity, and capability for simultaneous detection of multiple components, making it a key technology in the transformation of clinical testing [1]. Group 2: Clinical Applications - Mass spectrometry has been widely applied for the precise detection of small molecules and is gradually expanding into the detection of larger biomolecules such as proteins, peptides, and nucleic acids [1]. - The technology supports early disease screening, subtype diagnosis, and efficacy evaluation, providing reliable technical support for clinical applications [1]. Group 3: Upcoming Event - A network seminar titled "Fourth Clinical Mass Spectrometry Technology and Application Progress" is scheduled for June 12, 2025, organized by Instrument Information Network, to discuss the future development paths of clinical mass spectrometry [2][3].